

Cryoprecipitate, AHF

For Research or For Further Processing Use



Product Description

Cryoprecipitate is prepared from plasma that was separated from 500mL of whole blood and frozen within 24 hours of collection. This product contains Fibrinogen, Factor 8, Factor 13, von Willebrand factor and fibronectin. This product once used to treat patients with hemophilia, is primarily used today for its high fibrinogen content. The product volume is approximately 20mL and contains citrate-phosphate-dextrose (CPD) anticoagulant.

Product Source

Cryoprecipitate is manufactured from plasma derived from 500mL whole blood collections.

Product Processing

Frozen plasma is placed in a 1-6°C environment overnight. As the plasma slowly thaws the high molecular weight cold-insoluble components fall out of solution and collect in the bottom of the container. Cryo-reduced plasma is removed from the unit and the precipitate is frozen.

Product Testing

Monthly QC is performed on the production method to ensure that the method provides > 150mg of fibrinogen.

Product Storage

Product is store frozen at $\leq -20^{\circ}\text{C}$. Thawed product should be used within 24 hours.

Recommended Thawing Method

Place each unit in a zip lock bag and place into a 37°C water bath. Product should be completely thawed within 30 minutes.

Warning

This product is composed of human-derived materials. Always wear appropriate personal protective equipment when handling this product and treat it as potentially infectious, using Universal Precautions, regardless of the results of infectious disease testing.

Limitations and Publications

This product is for research use or therapeutic use only, not for resale. Nothing produced directly from this product may be sold. When publishing scientific results obtained using this product, acknowledge supplier as Bio-Sharing.org.